<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Most prevalent cancer types and known mechanisms for malignancy formation among patients with primary immunodeficiencies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Most prevalent cancer types and known mechanisms for malignancy formation among patients with primary immunodeficiencies</h1>
<div class="graphic"><div class="figure"><div class="ttl">Most prevalent cancer types and known mechanisms for malignancy formation among patients with primary immunodeficiencies</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="22%"></colgroup><colgroup width="10%"></colgroup><colgroup span="2" width="22%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease</td> <td class="subtitle1">Genetic defect or probable pathogenesis</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Mechanism of malignancy formation</td> <td class="subtitle1">Type of malignancy</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Combined immunodeficiencies</td> </tr> <tr> <td class="indent1">Severe combined immunodeficiency</td> <td>Mutations in <em>IL2RG</em>, <em>JAK3</em>, <em>IL7RA</em>, <em>RAG1</em>, <em>RAG2</em>, <em>DCLRE1C</em>, <em>CORO1A</em>, <em>CD3D</em>, <em>CD3E</em>, <em>CD3Z</em>, <em>PTPRC</em>, <em>PRKDC</em>, <em>ADA</em>, and <em>AK2</em></td> <td>AR in most cases, also XL</td> <td>Probably impaired function of immune system and decreased viral clearance (EBV)</td> <td> <p>NHL, Hodgkin lymphoma, leukemia</p> <p>Multiple renal and pulmonary leiomyomata</p> <p>EBV-associated lymphoma (Artemis)</p> Burkitt lymphoma (ADA deficiency treated with PEG-ADA)</td> </tr> <tr> <td class="indent1">ITK deficiency (an EBV-associated lymphoproliferative disease)</td> <td>Mutations in <em>ITK</em> (IL-2-inducible T cell kinase)</td> <td>AR</td> <td>Impaired function of immune system, decreased viral clearance (EBV)</td> <td>Lymphoma</td> </tr> <tr class="divider_bottom"> <td class="indent1">MAGT1 deficiency (ie, XMEN) </td> <td>Mutations in <em>MAGT1</em> (magnesium transporter 1)</td> <td> XL</td> <td> </td> <td>Lymphoma</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Well-defined syndromes with immunodeficiency</td> </tr> <tr> <td class="indent1">Wiskott-Aldrich syndrome</td> <td>Mutations in <em>WAS</em></td> <td>XL</td> <td>Impaired function of immune system, decreased viral clearance (EBV), probably impaired genetic stability</td> <td>Diffuse large B cell lymphomas, NHL of larynx, leukemia, cerebellar astrocytoma, Kaposi sarcoma, smooth muscle tumors</td> </tr> <tr> <td class="indent1">Ataxia-telangiectasia</td> <td>Mutations in <em>ATM</em></td> <td>AR</td> <td>Impaired genetic stability</td> <td>Lymphoid leukemias, lymphomas (both B and T cell, NHL), epithelial tumors</td> </tr> <tr> <td class="indent1">Nijmegen breakage syndrome</td> <td>Mutations in <em>NBS1</em></td> <td>AR</td> <td>Impaired genetic stability</td> <td>Brain tumors, lymphomas (both B and T, NHL, DLBCL and T-LBL), leukemia</td> </tr> <tr> <td class="indent1">Cartilage-hair hypoplasia</td> <td>Mutations in <em>RMRP</em></td> <td>AR</td> <td> </td> <td>NHL basal cell carcinoma</td> </tr> <tr> <td class="indent1">Autosomal dominant hyperimmunoglobulin E syndrome (AD-HIES)</td> <td>Mutations in <em>STAT3</em></td> <td>AD</td> <td> </td> <td>NHL, squamous cell carcinoma of the vulva, pulmonary adenocarcinoma with liver, bone, and spinal cord metastases</td> </tr> <tr class="divider_bottom"> <td class="indent1">AR-HIES (DOCK8 deficiency)</td> <td>Mutations in <em>DOCK8</em></td> <td>AR</td> <td>Probably defective tumor suppression genes in DOCK8 deficiency</td> <td>Squamous cell carcinoma, cutaneous T cell lymphoma/leukemia, Burkitt lymphoma</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Predominantly antibody deficiencies</td> </tr> <tr> <td class="indent1">X-linked agammaglobulinemia</td> <td>Mutations in <em>BTK</em></td> <td>XL</td> <td> </td> <td>Lymphoproliferative disorders, gastric adenocarcinoma, colorectal cancer</td> </tr> <tr> <td class="indent1">Common variable immunodeficiency</td> <td>Unknown in most cases, mutations in <em>TNFRSF13B </em>(encodes TACI), <em>TNFRSF13C </em>(encodes BAFF-R), CD19, CD20, CD81, and ICOS</td> <td>Variable</td> <td>Probably defective tumor suppression genes</td> <td>NHL, epithelial tumors (carcinomas of stomach, breast, bladder, cervix), carcinoma of the vulva (ICOS deficiency), tonsillar carcinoma of epithelial origin (TNFRSF13B)</td> </tr> <tr> <td class="indent1">X-linked hyperimmunoglobulin M syndrome</td> <td>Mutations in <em>CD40L</em></td> <td>XL</td> <td>Probably defective clearance of Cryptosporidium</td> <td>Carcinomas of the liver, pancreas, biliary tract and associated neuroectodermal endocrine cells</td> </tr> <tr> <td class="indent1">IgG subclass deficiency</td> <td>Unknown</td> <td>Variable</td> <td> </td> <td>Lymphoma</td> </tr> <tr class="divider_bottom"> <td class="indent1">Selective IgA deficiency</td> <td>Unknown</td> <td>Variable</td> <td> </td> <td>Lymphoma, gastrointestinal carcinoma</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Diseases of immune dysregulation</td> </tr> <tr> <td class="indent1">Chediak-Higashi syndrome</td> <td>Mutations in CHS1 (<em>LYST</em>) gene</td> <td>AR</td> <td> </td> <td>Lymphoma</td> </tr> <tr> <td class="indent1">Hermansky-Pudlak syndrome, type 2</td> <td>Mutations in <em>AP3B1</em> gene</td> <td>AR</td> <td> </td> <td>Lymphoma</td> </tr> <tr> <td class="indent1">Perforin deficiency, Familial hemophagocytic lymphohistiocytosis, type 2 (FHL2)</td> <td>Mutation in <em>PRF1</em></td> <td>AR</td> <td> </td> <td>Lymphoma</td> </tr> <tr> <td class="indent1">STXBP2 (Munc 18-2) deficiency, FHL5</td> <td>Mutation in <em>STXBP2</em></td> <td>AR</td> <td> </td> <td>Lymphoma</td> </tr> <tr> <td class="indent1">SH2DA1 deficiency, X-linked lymphoproliferative disease (XLP1)</td> <td>Mutations in <em>SH2D1A</em></td> <td>XL</td> <td>Impaired function of immune system, decreased viral clearance (EBV)</td> <td>Hodgkin B cell lymphoma, NHL in the intestinal region</td> </tr> <tr class="divider_bottom"> <td class="indent1">Autoimmune lymphoproliferative syndrome (ALPS)</td> <td>Mutations in <em>TNFRSF6</em></td> <td>AD (mostly)</td> <td>Probably defective tumor suppression genes</td> <td>Hodgkin lymphoma and NHL</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Phagocytic defects</td> </tr> <tr> <td class="indent1">Severe congenital neutropenia</td> <td>Mutations in <em>ELANE</em>, <em>HAX 1</em>, and <em>WASP</em></td> <td>AD, AR, or XL</td> <td>Genetic predisposition, iatrogenic (G-CSF treatment)</td> <td>Leukemia</td> </tr> <tr> <td class="indent1">Shwachman-Diamond syndrome</td> <td><em>SBDS</em>: Defective ribosome synthesis</td> <td>AR</td> <td>Probably iatrogenic (G-CSF treatment)</td> <td>Leukemia</td> </tr> <tr> <td class="indent1">Chronic granulomatous disease</td> <td>Mutations in <em>gp91phox</em>, <em>p22phox</em>, <em>p47phox</em>, <em>p67phox</em>, and <em>p40phox</em></td> <td>XL or AR</td> <td> </td> <td>Lymphoma, leukemia, retinoblastoma, melanoma, rhabdomyosarcoma of the liver, glioblastoma multiforme</td> </tr> <tr class="divider_bottom"> <td class="indent1">MonoMAC syndrome</td> <td><em>GATA2</em>: Loss of stem cells</td> <td>AD</td> <td> </td> <td>AML, CML, vulvar carcinoma, metastatic melanoma, cervical carcinoma, Bowen disease of the vulva, leiomyosarcoma</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Defects in innate immunity</td> </tr> <tr> <td class="indent1">WHIM syndrome</td> <td>Mutations in <em>CXCR4</em></td> <td>AD</td> <td>Decreased viral clearance</td> <td>HPV-related cancers, lymphoma</td> </tr> <tr> <td class="indent1">Epidermodysplasia verruciformis</td> <td>Mutations in <em>EVER1</em> and <em>EVER2</em></td> <td>AR</td> <td>Impaired function of immune system, decreased viral clearance (HPV), probably impaired genetic stability</td> <td>Squamous cell carcinoma</td> </tr> </tbody></table></div><div class="graphic_footnotes"><font color="red"><em><font color="black">IL2RG</font></em><font color="black">: gene for interleukin-2-receptor common gamma chain;<em> JAK</em>3: gene for Janus kinase 3; <em innerhtml="">IL7RA:</em> gene for interleukin-7-receptor alpha chain<em innerhtml="">; RAG1: </em>recombination-activating gene 1;<em innerhtml=""> RAG2: </em>recombination-activating gene 2<em innerhtml="">; DCLRE1C:</em> gene for DNA cross-link repair protein 1C<em innerhtml="">; </em>CORO1A<em innerhtml="">: </em>coronin 1<em innerhtml="">; </em>CD3D: CD3 delta; CD3E: CD3 epsilon; CD3Z: CD3 zeta; PTPRC: protein tyrosine phosphatase, receptor type C; PRKDC: protein kinase, DNA-activated, catalytic polypeptide<em innerhtml="">;</em></font></font><font color="black"> ADA: adenosine deaminase; AK2: mitochondrial adenylate kinase 2; </font>AR: autosomal <font color="black">recessive; XL: X-linked; EBV: Epstein-Barr virus; NHL: non-Hodgkin lymphoma; PEG-ADA: polyethylene glycol-modified bovine ADA; <em>ITK</em>: gene for IL-2-inducible T cell kinase;</font> IL-2: interleukin-2; XMEN: X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasm;<font color="black"> <em>WAS</em>: gene for Wiskott-Aldrich syndrome protein; <em>ATM</em>: ataxia-telangiectasia, mutated; <em>NBS1</em>: NBS gene 1; DLBCL: </font>diffuse large B cell lymphoma; <font color="black">T-LBL: T cell lymphoblastic leukemia/lymphoma; <em>RMRP</em>: ribonuclease mitochondrial RNA processing gene;</font> AD: autosomal dominant; HIES: hyperimmunoglobulin E syndrome; <font color="red"><em><font color="black">STAT3</font></em><font color="black">: gene for signal transducer and activator of transcription 3; <em>DOCK8</em>: gene for dedicator of cytokinesis 8; <em>BTK</em>: gene for Bruton tyrosine kinase; </font></font><font color="red"><font color="black">TACI: transmembrane activator and calcium-modulator and cyclophilin ligand; BAFF-R: B cell-activating factor of the tumor necrosis factor family receptor; ICOS: inducible costimulator of activated T cells;</font> <em><font color="black">CD40L</font></em><font color="black">: gene for CD40 ligand;</font></font> IgG: immunoglobulin G; IgA: immunoglobulin A; <font color="red"><em><font color="black">CHS1</font></em><font color="black">: Chediak-Higashi syndrome gene (also known as <em>LYST</em>); <em>AP3B1</em>: gene for adaptor-related protein complex 3, beta 1 subunit; <em>PRF1</em>: gene for perforin 1; <em>STXBP2</em>: gene for syntaxin binding protein 2; FHL5: familial hemophagocytic lymphohistiocytosis, type 5; <em>SH2DA1</em> (also known as <em>SAP</em>): gene for slam-associated protein;</font> <em><font color="black">TNFRSF6</font></em><font color="black">: tumor necrosis factor receptor superfamily, member 6 gene (codes for FAS receptor); <em>ELANE</em>: gene for neutrophil elastase; <em>HAX 1</em>: gene for XCLSI associated protein X-1; WASP: Wiskott-Aldrich syndrome protein; G-CSF: granulocyte colony-stimulating factor; <em>SBDS</em>: gene for Shwachman-Bodian Diamond syndrome; </font><em><font color="black">GATA2</font></em><font color="black">: gene for GATA-binding protein 2;</font></font> AML: acute myelogenous leukemia; CML: chronic myelogenous leukemia; <font color="red"><font color="black">WHIM: warts, hypogammaglobulinemia, infections, myelokathexis;</font> <font color="black">CXCR4: chemokine receptor 4;</font></font> HPV: human papillomavirus.</div><div id="graphicVersion">Graphic 96198 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
